Compare OZ & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OZ | LUCD |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.2M | 190.8M |
| IPO Year | 2020 | 2021 |
| Metric | OZ | LUCD |
|---|---|---|
| Price | $49.73 | $1.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 21.0K | ★ 684.5K |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,187,000.00 | $4,346,000.00 |
| Revenue This Year | N/A | $115.58 |
| Revenue Next Year | N/A | $130.54 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 243.44 | 79.00 |
| 52 Week Low | $48.50 | $0.95 |
| 52 Week High | $69.00 | $1.70 |
| Indicator | OZ | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 41.93 | 55.51 |
| Support Level | N/A | $1.01 |
| Resistance Level | $65.22 | $1.52 |
| Average True Range (ATR) | 2.08 | 0.08 |
| MACD | -0.49 | 0.02 |
| Stochastic Oscillator | 10.73 | 59.81 |
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset. The majority of the revenue is earn from mixed-use segment.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.